About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ALNY - Alnylam Pharmaceutic...| Previous Close | $139.02 | Open | $139.59 |
| Volume | 768.4K | Market Cap | 16.31B |
| Yield | Last Dividend |
| Alnylam's Oxalate-Lowering Therapy Shows... | 04/01/21 |
| Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatmen... | |
| Global Oligonucleotide Therapy Market Re... | 03/23/21 |
| DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMa... | |
| Alnylam to Present Full 9-Month Results ... | 03/23/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Compa... | |
| Transthyretin Amyloidosis Treatment Mark... | 03/08/21 |
| Transthyretin Amyloidosis Treatment Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic ... | |
| RNAi Therapeutics Market Insight & Futur... | 03/05/21 |
| The RNAi therapeutics market was valued at US$ 618.79 million in 2019 and is projected to reach US$ 1,209.29 million by 2027; it is expected to grow a... | |
| Alnylam to Webcast Presentation at 10th ... | 02/18/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that managemen... | |
| Chardan Capital Stick to Their Buy Ratin... | 02/12/21 |
| Chardan Capital Stick to Their Buy Rating for Alnylam Pharmaceuticals | |
| Oppenheimer Stick to Their Hold Rating f... | 02/12/21 |
| Oppenheimer Stick to Their Hold Rating for Alnylam Pharmaceuticals | |
| Alnylam Pharmaceuticals Reports Fourth Q... | 02/11/21 |
| Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth | |
| Earnings Scheduled For February 11, 2021 | 02/11/21 |
| Companies Reporting Before The Bell ??? Bluerock Residential Growth REIT, Inc. Class A Common Stock (AMEX: BRG ) is expected to report quarterly loss ... | |
| Global RNA Therapeutics Market Growth Fa... | 02/09/21 |
| A persuasive RNA Therapeutics report is an ideal guide to attain an information or key data about market, emerging trends, product usage, and motivati... | |
| Alnylam to Webcast Conference Call Discu... | 01/28/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will r... | |
| The Daily Biotech Pulse: Sorrento, Immut... | 01/27/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Ale... | |
| The Daily Biotech Pulse: Novartis Misses... | 01/26/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abb... | |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:AL... | 01/16/21 |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Laurie Keating sold 14,941 shares of the company???s stock in a transaction on Tuesday, January 12th. ... | |
| Alnylam Pharmaceuticals : Launches ??? P... | 01/10/21 |
| ??? New 5-Year Strategy Represents Alnylam???s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the Wo... | |
| Alnylam Launches ???Alnylam P5x25??? Str... | 01/10/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year... | |
| Berenberg Bank Stick to Their Hold Ratin... | 01/08/21 |
| Berenberg Bank Stick to Their Hold Rating for Alnylam Pharmaceuticals | |
| Needham Stick to Their Buy Rating for Al... | 01/07/21 |
| Needham Stick to Their Buy Rating for Alnylam Pharmaceuticals | |
| Alnylam Reports Positive Topline Results... | 01/07/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIO... | |
| Alnylam to Webcast Presentation at 39th ... | 01/04/21 |
| Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview a | |
| Global Antisense and RNAi Therapeutics M... | 12/31/20 |
| The forecast period 2020-2027 is going to be great for the Antisense and RNAi Therapeutics market which will be the face changer for Pharmaceutical in... | |
| Sage Therapeutics Announces the Appointm... | 12/16/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapi... | |
| Alnylam Announces 2021 Product and Pipel... | 12/15/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D D... | |
| Alnylam to Webcast Virtual R&D Day | 12/08/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will w... | |
| Alnylam Issues 2nd Annual Patient Access... | 12/07/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new report... | |
| Alnylam Completes Enrollment in ILLUMINA... | 12/03/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ac... | |
| The Week Ahead In Biotech: Hematology Co... | 11/29/20 |
| Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday. The... | |
| Attention Biotech Investors: Mark Your C... | 11/28/20 |
| The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied t... | |
| STAT+: Alnylam wins FDA approval for fir... | 11/24/20 |
| Alnylam Pharmaceuticals scored its third approval from the US Food and Drug Administration in as many years this week. | |
| Hold rating | 02/22/21 |
| Guggenheim downgrades from Buy to Neutral rating and announces Price Target of $162.00 | |
| Buy rating | 02/12/21 |
| Needham maintains Buy rating and raises Price Target from $160.00 to $180.00 | |
| Buy rating | 02/12/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $225.00 to $235.00 | |
| Strong Buy rating | 02/12/21 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $203.00 to $206.00 | |
| Hold rating | 02/12/21 |
| Citigroup downgrades from Buy to Neutral rating and raises Price Target from $170.00 to $175.00 | |
| Strong Buy rating | 02/12/21 |
| Barclays maintains Overweight rating and raises Price Target from $162.00 to $196.00 | |
| Buy rating | 01/25/21 |
| BMO Capital downgrades from Outperform to Market Perform rating and announces Price Target of $185.00 | |
| Date | 2021-02-11 (BMO) | Est. (EPS/Rev.) | ($1.76)/ 146.07M |
| Actual (EPS/Rev.) | $-1.60/ $163.56 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech and Bio Swing Trades | Matthew Burdeshaw | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
